Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.15 - $91.99
Previous CloseN/A
Volume7.58M
Average Volume (3M)9.08M
Market Cap
$10.39B
Enterprise Value$6.31B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$698.00M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Oct 30, 2025EPS Estimate
-2.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding389,079,740
10 Day Avg. Volume8,714,286
30 Day Avg. Volume9,081,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda-2.24
Forecast
1Y Price Target
$43.75Price Target Upside67.50% Upside
Rating ConsensusHold
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Cost ManagementAggressive cost cuts across the organization are promising signs that MRNA is taking steps to optimize its cost structure.
Financial PerformanceMRNA reported a 2Q topline beat driven by Spikevax, with product revenue of $114mn, which was above consensus estimates.
Product DevelopmentMono flu vaccine and combo flu+COVID vaccine are being prepped for FDA submission following positive phase 3 flu results.
Bears Say
COVID Revenue DependencyThe company’s near- and intermediate-term prospects are still largely tied to COVID revenue streams, which presents forecasting difficulty.
Revenue GuidanceMRNA lowered the upper-end of FY25 product revenue guidance to $1.5bn-$2.2bn from $1.5bn-$2.5bn prior due to a timing shift of deliveries of contracted revenue for the UK into 1Q26.
Workforce ReductionThe announcement of a workforce reduction of about 10% indicates a significant restructuring effort.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $23.15 and its highest was $91.99 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $10.39B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 30, 2025 which is in 81 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Aug 01, 2025. The company reported -$2.13 earnings per share for the quarter, beating the consensus estimate of -$2.989 by $0.859.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.07.
How many shares outstanding does Moderna have?
Moderna has 389,079,740 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.13 in its last earnings report, beating expectations of -$2.989. Following the earnings report the stock price went down -6.631%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.75 (67.50% Upside)
$43.75 (67.50% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 658.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.36%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
-23.41%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. The company is involved in the development and commercialization of mRNA-based vaccines and therapeutics across various therapeutic areas, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna's most notable product is its COVID-19 vaccine, which has played a significant role in addressing the global pandemic.
MRNA Company Deck
MRNA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments such as FDA approvals and substantial cost reductions, alongside challenges including a significant revenue decline and workforce restructuring. While there are promising advancements in the pipeline and financial discipline is evident, the financial performance and external shipment delays present notable concerns.View all MRNA earnings summariesMRNA Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
MRNA Stock 12 Month Forecast
Average Price Target
$43.75
▲(67.50% Upside)
Technical Analysis
Ownership Overview
7.79% Insiders
19.69% Mutual Funds
0.36% Other Institutional Investors
48.19% Public Companies and Individual Investors